Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glaucoma neuroprotection: What is it? Why is it needed?

Literature DB >> 17508033

Glaucoma neuroprotection: What is it? Why is it needed?

Abstract

The glaucomas are a group of ocular diseases characterized by progressive optic nerve damage and visual loss. Although there is good laboratory evidence for glaucoma neuroprotection by several drugs, the evidence from randomized clinical trials is lacking.

Entities: Disease

Mesh：

Substances：
Neuroprotective Agents

Year: 2007 PMID： 17508033 DOI： 10.3129/can j ophthalmol.i07-045

Source DB: PubMed Journal: Can J Ophthalmol ISSN： 0008-4182 Impact factor: 1.882

Keyword Cloud
Cited

26 in total

Review 1. Neuroprotection in glaucoma: drug-based approaches.

Authors: William Cheung; Li Guo; M Francesca Cordeiro
Journal: Optom Vis Sci Date: 2008-06 Impact factor: 1.973

2. TRPC6: an underlying target for human glaucoma.

Authors: Qian Fan; Wen-Bin Huang; Xiu-Lan Zhang
Journal: Int J Ophthalmol Date: 2012-08-18 Impact factor: 1.779

3. Histological, morphometric, protein and gene expression analyses of rat retinas with ischaemia-reperfusion injury model treated with sildenafil citrate.

Authors: Diogo S Zanoni; Germana A Da Silva; Raaya Ezra-Elia; Márcio Carvalho; Juliany G Quitzan; Ron Ofri; José L Laus; Renee Laufer-Amorim
Journal: Int J Exp Pathol Date: 2017-06 Impact factor: 1.925

4. TGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice.

Authors: Swarup S Swaminathan; Dong-Jin Oh; Min Hyung Kang; Allan R Shepard; Iok-Hou Pang; Douglas J Rhee
Journal: Invest Ophthalmol Vis Sci Date: 2014-06-06 Impact factor: 4.799

5. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram.

Authors: Benedetto Falsini; Dario Marangoni; Tommaso Salgarello; Giovanna Stifano; Lucrezia Montrone; Salvatore Di Landro; Laura Guccione; Emilio Balestrazzi; Alberto Colotto
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-03-17 Impact factor: 3.117

6. Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

Authors: Jessica A Cooke; Jason S Meyer
Journal: Curr Ophthalmol Rep Date: 2015-08-07

Glaucoma neuroprotection: What is it? Why is it needed?

Review 1. Neuroprotection in glaucoma: drug-based approaches.

2. TRPC6: an underlying target for human glaucoma.

3. Histological, morphometric, protein and gene expression analyses of rat retinas with ischaemia-reperfusion injury model treated with sildenafil citrate.

4. TGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice.

5. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram.

6. Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

7. Overexpression of SPARC in human trabecular meshwork increases intraocular pressure and alters extracellular matrix.

8. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons.

9. The papilla as screening parameter for early diagnosis of glaucoma.

10. The East London glaucoma prediction score: web-based validation of glaucoma risk screening tool.